Anjil Giri, Ph.D. is the Head of Technical Operations at Skylark Bio, with responsibilities spanning internal and external vector manufacturing, process and analytical development, supply chain, as well as quality control activities. Dr. Giri is an accomplished technical operations leader with experience in bioprocessing and CMC development for gene therapies and traditional biologics.

Most recently, Dr. Giri was the Head of CMC Development at PTC Therapeutics, where he oversaw CMC strategy and development of PTC’s portfolio of AAV gene therapy candidates for CNS and ocular indications, including EU and UK approval of Upstaza, the first AAV gene therapy molecule delivered directly to the brain. Prior to PTC, Dr. Giri held TechOps roles of increasing responsibilities at Tesaro-GSK and Alexion Pharmaceuticals, where he contributed to the development and commercialization of monoclonal and bispecific antibodies, including Ultomiris and Jemperli.

Dr. Giri’s work in academia and industry has resulted in 10 peer-reviewed publications with over 900 citations, and a patent. He received a Ph.D. in Chemical Engineering from Johns Hopkins University and a Bachelor’s in Biological Systems Engineering from the University of Idaho.